Improving Drug Therapies a Single Cell at a Time using Single Cell ICP-MS
12 Jun 2017

It is estimated that in 2017, over 1.6 million new cancer cases will be diagnosed. Cisplatin and other platinum-based analogs, remain a mainstay in the clinic treating a wide range of tumors including ovarian, lung, testicular, bladder, as well as others. Frequently the patient initially responds to chemotherapy but when the tumor returns, patients are resistant to further platinum-based chemotherapy. With new research, we are taking a cellular step closer to understanding how Cisplatin chemotherapy, and other metal-based cancer drugs, can be developed to improve their success rates. In this webinar, we will discuss the use of single cell ICP-MS (SC-ICP-MS) in enabling researchers to see how effective a cancer drug is being targeted to each and every cancer cell.

Key Learnings:

  • Single cell ICP-MS analysis methodology
  • Quantifying single cell uptake with Cisplatin
  • Novel targets for increasing Cisplatin uptake
  • Overcoming current challenges with drug uptake analysis

PerkinElmer, Inc.